Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
Telomir Pharmaceuticals announced that its investigational compound, Telomir-1, has shown efficacy in killing aggressive human leukemia cells in vitro. This finding expands Telomir-1’s oncology profile beyond its previously reported activity in other cancer models, potentially enhancing its relevance in cancer treatment by targeting intracellular iron modulation and epigenetic regulation.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapies targeting the epigenetic and metabolic roots of cancer, aging, and age-related diseases.
Average Trading Volume: 3,014,120
Technical Sentiment Signal: Sell
Current Market Cap: $49.16M
For an in-depth examination of TELO stock, go to TipRanks’ Overview page.